ProShare Advisors LLC Grows Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

ProShare Advisors LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 20.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 123,097 shares of the company's stock after purchasing an additional 20,557 shares during the period. ProShare Advisors LLC owned about 0.15% of IDEXX Laboratories worth $50,893,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Hurley Capital LLC purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $29,000. Rialto Wealth Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $31,000. Colonial Trust Co SC grew its stake in IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares in the last quarter. Finally, Kestra Investment Management LLC bought a new position in IDEXX Laboratories in the fourth quarter worth approximately $38,000. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock traded down $8.05 during mid-day trading on Wednesday, reaching $509.11. The company had a trading volume of 261,885 shares, compared to its average volume of 806,239. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock's 50-day simple moving average is $435.69 and its 200-day simple moving average is $432.77. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $530.60. The company has a market capitalization of $40.94 billion, a P/E ratio of 47.71, a P/E/G ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. IDEXX Laboratories's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business earned $2.71 EPS. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on IDXX shares. Barclays increased their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Stifel Nicolaus lifted their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley raised their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Finally, StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.